• Sorry! To unlock all site features, we'll need to collect some information from you.
  • Unit 7.5: Monitoring and Complications of Anticoagulation

    David Schneider, MD — University of Vermont

    Duration:1 hour

    Faculty Disclosure

    • Grant and/or Research Support: The Medicines Company; Guilford Pharmaceuticals
    • Consultant: Johnson & Johnson ; Sanofi-Aventis; Astra Zeneca
    • Other Financial or Material Support: Merck

    Learning Objectives

    • Objectives of monitoring antithrombotic therapy
    • Platelet function as a cardiac risk factor
    • Complications of antithrombotic therapy